We believe that optimization of CD19 CAR-targeted T cell therapy for B-ALL requires an immunocompetent and physiologically relevant mouse model of B-ALL to address critical questions regarding CAR modified T cell therapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.